GENETICS OF PREMENSTRUAL DYSPHORIC DISORDER

Thesis

Submitted for Partial Fulfilment of the Requirements of MD. DEGREE IN Obstetrics and Gynaecology

Presented By

Maged Mahmoud Ali Ahmed Elshourbagy

M.B.B.Ch, 2000 – Ain Shams University M.SC. Obstetrics and Gynecology; Ainshams University; 2005

Under the Supervision of

Prof. Dr. Mohamed Nabegh Elmahallawy

Prof. of Obstetrics and Gynaecology Faculty of Medicine Ain shams University

Prof. Dr. Waleed Hitlar Tantawy

Prof. of Obstetrics and Gynaecology Faculty of Medicine- Ain shams University

Prof. Dr Shaughn O'Brien

Head of the Academic Unit of Obstetrics and Gynaecology, Keele University School of Medicine

Prof.Dr. Khaled M K Ismail

Professor of Obstetrics and Gynaecology, University of Birmingham

Faculty of Medicine Ain Shams University, Cairo, Egypt. 2014





Thanks first and last to **ALLAH** for granting me to complete this work. I owe to Allah for his support and guidance in every step in my life.

At the outset, I express my gratitude to my supervisors **Prof. Dr. NabeghElmahallawy**and **Prof. Dr. WaleedHitlarTantawy**for their invaluable support.

I am highly grateful to **Prof. Sahughn O'Brien** and **Prof. KhaledMostafaKamel**for giving me the opportunity to undertake this research and their continued advice and guidance throughout the project.

I am particularly grateful to Mrs Julia Magnayfor all her help in the laboratory work and the research paper written.

Acknowledgement must also be given to the Ain Shams University and the Delegation administer for funding the Whole research.

Last but not least, I would like to thank my mother, father and my wife for helping me tocomplete this work.

List of Contents

Title	Page No.
List of Abbreviations	ii
List of Tables	V
List of Figures	vi
Introduction	1
Aim of the work	4
Review of Literature	
Study Participants and Methods	74
Results	
Discussion	121
Summary and Conclusion	136
References	140
Annexes	185
Arabic Summary	

Glossary	of	Terms
Olobbal		

Allele...... One of the variant forms of a gene at a particular locus.

Exon...... A nucleotide sequence in DNA that carries the code for the final messenger RNA molecule and thus defines a protein's amino acid sequence.

Gene..... The functional and physical unit of heredity passed from parent to offspring.

Genotype.... The genetic identity of an individual that does not show as outward characteristics.

Intron A non-coding region of DNA that is originally copied into RNA but is cut out of the final RNA transcript.

Linkage The association of genes and/or markers that lie near each other on a chromosome. Linked genes and markers tend to be inherited together.

Nucleotide... One of the structural components of DNA and RNA, consisting of a base (guanine, thymine, adenine or cytosine) plus a molecule of sugar and one of phosphoric acid.

PCR Polymerase chain reaction) A fast, inexpensive technique for making an unlimited number of copies of any piece of DNA.

Glossary of Terms_(Cont...)

Phenotype... The observable traits or characteristics of an organism, such as hair colour, weight, presence or absence of disease.

Polymorphism A common variant in the sequence of DNA among individuals.

Promoter.... The part of a gene that contains the information to turn the gene on or off. The process of transcription is initiated at the promoter.

RFLP...... Restriction fragment length polymorphisms) genetic variations at a site where a restriction enzyme cuts a piece of DNA. Such variations affect the size of the resulting fragments.

single nucleotide polymorphism) common, single nucleotide variations that occur in human DNA at a frequency of one every 1,000 bases

List of Abbreviations

CI..... Confidence interval

CNS..... Central nervous system

COPE..... Calendar of premenstrual experience

CRH...... Corticotrophin-releasing hormone

DNA Dexoribonucleic acid

DRSP Daily Record of Severity of Problems

FBC..... Full blood count

FSH Follicle-stimulating hormone

GABA Gamma amino butyric acid

GnRHa Gonadotrophic releasing hormone analogues

HRT Hormone replacement therapy

LD..... Linkage disequilibrium

LH Luteinising hormone

MAOA..... Monoamine oxidase A

PMDD..... Premenstrual Dysphoric Disordrer

PMS..... Premenstrual Syndrome

RCT..... Randomised controlled trial

RFLP Restriction fragment length polymorphism

SNP..... Single-nucleotide polymorphism

SSRIs..... Selective serotonin reuptake inhibitors

STR Short tandem repeat

Taq Thermus aquaticus

5-HT..... Serotonin`

List of Tables

Table No.	Title Page No	
Table (1):	Criteria for diagnosis of premenstrual dysphoric disorder	23
Table (2):	DSM-IV research criteria for premenstrual dysphoric disorder	24
Table (3):	The American Psychiatric Association DSM-5 criteria for diagnosing PMDD.	27
Table (4):	Differential diagnosis of premenstrual dysphoric disorder	29
Table (5):	The 5-HTTLPR gene polymorphisms distribution in women with PMDD and controls.	. 102
Table (6):	The rs25531 gene polymorphisms distribution in women with PMDD and controls.	. 104
Table (7):	Triallelic classification (5-HTTLPT/rs25531) gene polymorphisms distribution in women with PMDD and controls.	. 107
Table (8):	Functional Classification of 5-HTTLPT/rs25531 gene polymorphisms distribution in women with PMDD and controls.	. 109
Table (9):	Balletic Frequencies in women with PMDD and controls	. 113
Table (10):	A/G SNP (rs25531) frequency in women with PMDD and controls.	. 115
Table (11):	Triallelic Frequencies (5-HTTLPR/ rs25531)in women with PMDD and controls.	. 117
Table (12):	Functional allelic frequency in women with PMDD and controls.	. 119

List of Figures

Fig. No.	Title	age No.	
Figure (1):	An image captured using UVP ImageStore she the genotypes L/S, S/S and L/L respectively		98
Figure (2):	An image captured using UVP ImageStore she the genotypes La/lg, la/S and La/La respective	_	8
Figure (3):	The 5-HTTLPR gene polymorphisms distribut women with PMDD (n= 53))2
Figure (4):	The 5-HTTLPR gene polymorphisms distribut controls)3
Figure (5):	The 5-HTTLPR gene polymorphisms distribut women with PMDD and controls.)3
Figure (6):	The rs25531 gene polymorphisms distribution women with PMDD.)5
Figure (7):	The rs25531 gene polymorphisms distribution controls.)5
Figure (8):	Triallelic classification (5-HTTLPT/rs25531) polymorphisms distribution in controls.	_)7
Figure (9):	Triallelic classification (5-HTTLPT/rs25531) polymorphisms distribution in women with PMD	_)8
Figure (10):	Triallelic classification (5-HTTLPT/rs25531) polymorphisms distribution in women with PMD controls.	D and)8
Figure (11):	Functional Classification of 5-HTTLPT/rs25531 polymorphisms distribution in women with PMD		0
Figure (12):	Functional Classification of 5-HTTLPT/rs25531 polymorphisms distribution in controls.	_	0
Figure (13):	Functional Classification of 5-HTTLPT/rs25531 polymorphisms distribution in PMDD and control	_	1
Figure (14):	Balletic Frequencies in women with PMDD	11	4
Figure (15)	Biallelic Frequencies in controls	11	4

List of Figures_(Cont...)

Fig. No.	Title	Page No	0.
Figure (16):	Triallelic Frequencies (5-HTTLPR/ rs25531)in with PMDD.		.117
Figure (17):	Triallelic Frequencies (5-HTTLPR/ rs255 controls		.118
Figure (18):	Triallelic Frequencies (5-HTTLPR/ rs25531)in with PMDD and controls		.118
Figure (19):	Functional allelic frequency in women with PM	IDD	.119
Figure (20):	Functional allelic frequency in controls		. 120
Figure (21):	Functional allelic frequency in women with PM controls		

INTRODUCTION

recurrent psychologic and/or somatic symptoms that occur specifically during the luteal phase of the menstrual cycle, and resolve by menstruation. Premenstrual dysphoric disorder (PMDD) is the extreme, predominantly psychologic end of the PMS spectrum, and is estimated to occur in 3% to 8% of women with PMS. Premenstrual syndrome (PMS) can be a source of real distress and discomfort to menstruating women (Angst et al., 2001).

The definitive aetiology of PMS remains obscure. The current predominant theory proposes that women who develop PMDD have an underlying dysregulation of the serotonergic system and that the normal hormonal changes occurring during the luteal phase seem to amplify this condition, precipitating the occurrence of PMDD in susceptible individuals. Suppression of the normal hormonal changes occurring during the luteal phase by GnRH analogues or prolonging serotonin activity at the synapseby selective serotonin reuptake inhibitors (SSRIs) havetherapeutic effectiveness in the treatment of severe PMS and PMDD. SSRIs have comparable effectiveness to GnRH analogues; they are effective in up to 70% of women suffering with these disorders (Eriksson et al., 2008).

Evidence from family and twin studies suggests that genetic factors contribute to PMDD (*Kendler et al., 1992*). These findings made the researchers hypothesized that PMS/PMDD is at least in part genetically determined, and furthermore, that the serotonergic system is involved and it is essential to determine whether specific polymorphic genotypes are associated with the occurrence of PMDD (*Magnay et al., 2006*).

The most thoroughly studied serotonin-related gene is the one encoding the serotonin transporter (5-HTT) which is also called SLC6A4. The Serotonin-transporter-linked polymorphic region (5-HTTLPR) is an insertion/deletion polymorphism in the promoter region of the SLC6A4, resulting in one short allele (S allele) and one long allele (L allele). The S allele of the 5-HTTLPR gives rise to a lower invitro transcriptional activity of the 5-HTT. The S allele has also been associated with low serotonergic function as measured by a reduced prolactin response to serotonin-releasing agents, as well as with reduced platelet serotonin uptake. The same allele has also been associated with increased the catabolism of serotonin (*Bellivier*, *Roy and Leboyer*, *2002*; *Bah et al*, *2008*).

Single nucleotide polymorphism (SNP) in the region rs25531 (A and G alleles) was detected in repeat 6 of the 5-HTTLPR of long allele (L allele), also the S allele carries this

polymorphism. Because of their close proximity, 5-HTTLPR and rs25531 are strongly linked. The SNP can be found in the context of both L and S alleles. However, the combination SG is rare, thus many studies currently consider 5-HTTLPR as a triallelic marker: LA, LG and S (A or G). Functionally, the allelic composites LG and S (A or G) are associated with low, nearly equivalent expression of the transporter protein relative to LA allele (*Hu et al., 2006*). Out of those carrying the long 5-HTTLPR allele, 10% carry a G allele on the rs25531 locus, resulting in altered affinity for the transcription factor, and thus lower promoter activity, rendering the serotonin transporter availability similar to that of carriers of the S allele (*Nakamura et al, 2000; Wendland et al 2006*).

Previous studies failed to demonstrate significant 5-HTTLPR genotype and allele differences between women with PMDD and control subjects (*Melke et al, 2003 and Magnay et al, 2006*). However, these studies did not take into consideration the effect the SNP rs2553 in the women carring the long allele. It becomes esstional first to investigate whether rs25531 per se is a risk factor for premenstrual dysphoric disorder. Second, to determine whether reclassification of the 5-HTTLPR L allele into the high-activity LA and low-activity LG variants results in a significant association of genotype or haplotype with PMDD.

AIM OF THE WORK

The aim of the current study is to investigate whether rs25531 per se is a risk factor for premenstrual dysphoric disorder. Second, to determine whether reclassification of the 5-HTTLPR L allele into the high-activity LA and lowactivity LG variants results in a significant association of genotype or haplotype with PMDD.

Premenstrual Dysphoric Disorder

History of PMDD:

remenstrual syndrome first appeared in the medical literature in 1931 in two papers, one by German psychoanalyst Karen Horney and another more influential paper by American gynecologist Robert Frank(Horney 1931; Frank, 1931). Research on this condition was pursued on a small scale. However, intensified public awareness emerged out of controversies in the 1980s. First, in three widely publicized criminal trials held in the UK in 1980, defendants successfully pleaded diminished women responsibility or mitigation due to premenstrual syndrome in crimes of manslaughter, arson and assault. These trials received wide attention in the popular press(*Dalton*, 1980).

Premenstrual dysphoric disorderhas not been widely accepted as a condition distinct from PMS by most doctors and regulatory agencies or by those producing disease classification systems like the International Classification of Diseases (ICD) (*Knaapen et al., 2008*).

Premenstrual dysphoric disorder was first defined in 1987 in the Diagnostic and Statistical Manual of Mental